Is Psychemedics Stock a Good Investment?
Psychemedics Investment Advice | PMD |
- Examine Psychemedics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Psychemedics' leadership team and their track record. Good management can help Psychemedics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact Psychemedics' business and its evolving consumer preferences.
- Compare Psychemedics' performance and market position to its competitors. Analyze how Psychemedics is positioned in terms of product offerings, innovation, and market share.
- Check if Psychemedics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Psychemedics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Psychemedics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Psychemedics is a good investment.
Sell | Buy |
Buy
Market Performance | OK | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Psychemedics Stock
Researching Psychemedics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 23.0% of the company outstanding shares are owned by corporate insiders. The book value of Psychemedics was at this time reported as 0.99. The company recorded a loss per share of 0.79. Psychemedics last dividend was issued on the 24th of May 2023. The entity had 1:4 split on the 1st of August 2002.
To determine if Psychemedics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Psychemedics' research are outlined below:
| Psychemedics had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 22.1 M. Reported Net Loss for the year was (4.15 M) with profit before taxes, overhead, and interest of 9.29 M. | |
| Psychemedics has about 1.79 M in cash with (1.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Psychemedics has a poor financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from channelnewsasia.com: Commentary Restrict able-bodied users from PMAs, but dont make it harder for those with real need |
Psychemedics Quarterly Accounts Payable |
|
Psychemedics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Psychemedics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Psychemedics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Psychemedics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Psychemedics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Psychemedics backward and forwards among themselves. Psychemedics' institutional investor refers to the entity that pools money to purchase Psychemedics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 11.5 K | Crawford Investment Counsel, Inc | 2024-06-30 | 10 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6 K | Tower Research Capital Llc | 2024-06-30 | 3.6 K | Your Advocates Ltd., Llp | 2024-06-30 | 2.5 K | Fmr Inc | 2024-06-30 | 740 | Advisor Group Holdings, Inc. | 2024-06-30 | 257 | Caldwell Sutter Capital Inc | 2024-09-30 | 250 | Royal Bank Of Canada | 2024-06-30 | 50.0 | 22nw, Lp | 2024-06-30 | 274.4 K | Renaissance Technologies Corp | 2024-06-30 | 257 K |
Psychemedics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 13.79 M.Market Cap |
|
Psychemedics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.30) | |
| Return On Capital Employed | (0.34) | (0.32) | |
| Return On Assets | (0.31) | (0.30) | |
| Return On Equity | (0.62) | (0.59) |
Determining Psychemedics' profitability involves analyzing its financial statements and using various financial metrics to determine if Psychemedics is a good buy. For example, gross profit margin measures Psychemedics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Psychemedics' profitability and make more informed investment decisions.
Psychemedics' Earnings Breakdown by Geography
Please note, the presentation of Psychemedics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Psychemedics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Psychemedics' management manipulating its earnings.
Evaluate Psychemedics' management efficiency
Psychemedics has Return on Asset of (0.1624) % which means that on every $100 spent on assets, it lost $0.1624. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6133) %, meaning that it generated no profit with money invested by stockholders. Psychemedics' management efficiency ratios could be used to measure how well Psychemedics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.3. The current year's Return On Capital Employed is expected to grow to -0.32. At present, Psychemedics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 663.6 K, whereas Other Assets are forecasted to decline to about 1.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.16 | 1.50 | |
| Tangible Book Value Per Share | 1.16 | 1.50 | |
| Enterprise Value Over EBITDA | (69.02) | (65.57) | |
| Price Book Value Ratio | 2.55 | 2.42 | |
| Enterprise Value Multiple | (69.02) | (65.57) | |
| Price Fair Value | 2.55 | 2.42 | |
| Enterprise Value | 23.8 M | 44.4 M |
Psychemedics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.674 |
Basic technical analysis of Psychemedics Stock
As of the 8th of November, Psychemedics holds the Coefficient Of Variation of 928.25, semi deviation of 1.8, and Risk Adjusted Performance of 0.0923. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Psychemedics, as well as the relationship between them. Please check Psychemedics information ratio, and the relationship between the downside deviation and value at risk to decide if Psychemedics is priced some-what accurately, providing market reflects its current price of 2.34 per share. Please also confirm Psychemedics total risk alpha, which is currently at (0.47) to check out the company can sustain itself at a future point.Psychemedics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Psychemedics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Psychemedics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Psychemedics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kamin Peter over a month ago Acquisition by Kamin Peter of 627 shares of Psychemedics at 6.52 subject to Rule 16b-3 | ||
Weinert Fred J over two months ago Disposition of 1000 shares by Weinert Fred J of Psychemedics subject to Rule 16b-3 | ||
Kamin Peter over three months ago Discretionary transaction by Kamin Peter of tradable shares of Psychemedics subject to Rule 16b-3 | ||
Shoemaker Shannon over a year ago Psychemedics exotic insider transaction detected | ||
Weisenhoff Michael over a year ago Acquisition by Weisenhoff Michael of 4000 shares of Psychemedics subject to Rule 16b-3 | ||
Weisenhoff Michael over a year ago Psychemedics exotic insider transaction detected | ||
Michael Schaffer over a year ago Payment of 375 shares by Michael Schaffer of Psychemedics subject to Rule 16b-3 | ||
Michael Schaffer over a year ago Payment of 337 shares by Michael Schaffer of Psychemedics subject to Rule 16b-3 | ||
Fred Weinert over a year ago Acquisition by Fred Weinert of 1800 shares of Psychemedics subject to Rule 16b-3 |
Psychemedics' Outstanding Corporate Bonds
Psychemedics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Psychemedics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Psychemedics bonds can be classified according to their maturity, which is the date when Psychemedics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US744320BH48 Corp BondUS744320BH48 | View | |
| US744320BF81 Corp BondUS744320BF81 | View | |
| PRU 6 01 SEP 52 Corp BondUS744320BK76 | View | |
| PRU 5125 01 MAR 52 Corp BondUS744320BJ04 | View | |
| PRUDENTIAL FINL INC Corp BondUS744320BA94 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US744320AV41 Corp BondUS744320AV41 | View | |
| PRUDENTIAL FINL INC Corp BondUS744320AY89 | View |
Understand Psychemedics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Psychemedics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0923 | |||
| Market Risk Adjusted Performance | 11.26 | |||
| Mean Deviation | 1.33 | |||
| Semi Deviation | 1.8 | |||
| Downside Deviation | 2.62 | |||
| Coefficient Of Variation | 928.25 | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.58 | |||
| Information Ratio | 0.0607 | |||
| Jensen Alpha | 0.4088 | |||
| Total Risk Alpha | (0.47) | |||
| Sortino Ratio | 0.0914 | |||
| Treynor Ratio | 11.25 | |||
| Maximum Drawdown | 29.04 | |||
| Value At Risk | (1.30) | |||
| Potential Upside | 1.74 | |||
| Downside Variance | 6.86 | |||
| Semi Variance | 3.26 | |||
| Expected Short fall | (2.11) | |||
| Skewness | 4.88 | |||
| Kurtosis | 35.4 |
| Risk Adjusted Performance | 0.0923 | |||
| Market Risk Adjusted Performance | 11.26 | |||
| Mean Deviation | 1.33 | |||
| Semi Deviation | 1.8 | |||
| Downside Deviation | 2.62 | |||
| Coefficient Of Variation | 928.25 | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.58 | |||
| Information Ratio | 0.0607 | |||
| Jensen Alpha | 0.4088 | |||
| Total Risk Alpha | (0.47) | |||
| Sortino Ratio | 0.0914 | |||
| Treynor Ratio | 11.25 | |||
| Maximum Drawdown | 29.04 | |||
| Value At Risk | (1.30) | |||
| Potential Upside | 1.74 | |||
| Downside Variance | 6.86 | |||
| Semi Variance | 3.26 | |||
| Expected Short fall | (2.11) | |||
| Skewness | 4.88 | |||
| Kurtosis | 35.4 |
Consider Psychemedics' intraday indicators
Psychemedics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Psychemedics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Psychemedics Corporate Filings
| 18th of October 2024 Other Reports | ViewVerify | |
| 16th of October 2024 Other Reports | ViewVerify | |
| 3rd of September 2024 Other Reports | ViewVerify | |
F3 | 13th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Psychemedics Stock media impact
Far too much social signal, news, headlines, and media speculation about Psychemedics that are available to investors today. That information is available publicly through Psychemedics media outlets and privately through word of mouth or via Psychemedics internal channels. However, regardless of the origin, that massive amount of Psychemedics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Psychemedics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Psychemedics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Psychemedics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Psychemedics alpha.
Psychemedics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Psychemedics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Psychemedics Corporate Management
| Michael Schaffer | VP of Laboratory Operations | Profile | |
| Michael Weisenhoff | Principal Manager | Profile | |
| Charles IV | Ex VP | Profile | |
| Shannon Shoemaker | Chief Officer | Profile | |
| Werner Baumgartner | Founder | Profile | |
| Annette Baumgartner | Founder | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psychemedics. If investors know Psychemedics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psychemedics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Earnings Share (0.79) | Revenue Per Share 3.586 | Quarterly Revenue Growth (0.15) | Return On Assets (0.16) |
The market value of Psychemedics is measured differently than its book value, which is the value of Psychemedics that is recorded on the company's balance sheet. Investors also form their own opinion of Psychemedics' value that differs from its market value or its book value, called intrinsic value, which is Psychemedics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psychemedics' market value can be influenced by many factors that don't directly affect Psychemedics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Psychemedics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Psychemedics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psychemedics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.